Ablexis and AlivaMab Discovery Services together launch antibody drug discovery and development projects ... quality therapeutic leads on a rapid timeline, producing diverse antibodies against ...

The market is projected to grow from $11B in 2024 to $40B by 2030, driven by both conventional bispecifics and advancements such as antibody-drug and radioligand conjugates. 2 Invenra has launched ...

Biotechnology company YUMAB, a global provider of fully human monoclonal antibody (mAb) discovery ... antibody–drug conjugates, all of which require robust and rapid antibody development platforms.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set ...

“We are excited to deploy Biocytogen’s cutting-edge platforms for antibody discovery to support Adcendo’s innovative ADC drug development initiatives,” said Yuelei Shen, Ph.D., president ...

Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...

In another example of the pharma industry embracing generative artificial intelligence (GenAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibody discovery and development.

It’s one of the few AI drug discovery ... than existing antibody discovery methods which are effective but can be limited and costly. The technology will “enable the development of drugs ...